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D-Phenylglycine aminotransferase (D-PhgAT) –
substrate scope and structural insights of a
stereo-inverting biocatalyst used in the
preparation of aromatic amino acids†‡
Annabel Serpico,§a Silvia De Cesare,a Jon Marles-Wright, b M. Kalim Akhtar, ¶c
Gary J. Loakec and Dominic J. Campopiano *a
Enantiopure amines are key building blocks in the synthesis of many pharmaceuticals, so a route to their
production is a current goal for biocatalysis. The stereo-inverting D-phenylglycine aminotransferase
(D-PhgAT), isolated from Pseudomonas stutzeri ST-201, catalyses the reversible transamination from
L-glutamic acid to benzoylformate, yielding α-ketoglutarate and D-phenylglycine (D-Phg). Detailed kinetic
analysis revealed a range of amine donor and acceptor substrates that allowed the synthesis of enantiopure
aromatic D-amino acids at a preparative scale. We also determined the first X-ray crystal structure of
D-PhgAT with its bound pyridoxal 5′-phosphate (PLP) cofactor at 2.25 Å resolution. A combination of
structural analysis and site-directed mutagenesis of this class III aminotransferase revealed key residues that
are potentially involved in the dual substrate recognition, as well as controlling the stereo-inverting
behaviour of D-PhgAT. Two arginine residues (Arg34 and Arg407) are involved in substrate recognition
within P and O binding pockets respectively. These studies lay the foundation for further enzyme
engineering and promote D-PhgAT as a useful biocatalyst for the sustainable production of high value,
aromatic D-amino acids.
Introduction
The non-proteinogenic amino acids D-phenylglycine (D-Phg) and
D-4-hydroxyphenylglycine (D-Hpg) are fundamental side chain
building blocks in many antimicrobial compounds, including
the amoxicillin and vancomycin group of antibiotics.1,2 Existing
synthetic methods for the preparation of D-Phg and its
derivatives rely on toxic cyanide chemistry and multi-step
processes.3 Alternative biocatalytic methods are limited by
substrate solubility (e.g. the coupled hydantoinase/carbamoylase
system), or rely on a D-amino acid aminotransferase that uses
the costly D-amino acid donor and requires an additional
enzyme (a racemase) to yield the desired product.4,5
Aminotransferases (ATs, also known as transaminases, TAs or
ATAs, EC 2.6.1)6 are a large superfamily of pyridoxal 5′-
phosphate (PLP)-dependent enzymes with a rapidly expanding
range of industrial applications for the production of diverse
compounds containing a chiral amine functionality.7–15 For
example, they have been shown to be a suitable replacement for
a transition metal catalyst during the preparation of drugs such
as sitagliptin.16 ATs use PLP to catalyze the transfer of an amino
group between an amino donor and an amino acceptor via a
ping-pong, bi–bi mechanism via a pyridoxamine (PMP) form of
the cofactor (Scheme 1).
The 3D structures of many PLP enzymes have been
determined and they display seven different folds with TAs
typically found in classes I and IV.17–22 To determine the
substrate scope of so many AT-catalysed reactions, powerful
high-throughput assays have been developed that can be
used to study the activities of wild-type ATs or identify new
substrates for engineered enzymes.23–27
The X-ray structures and screening methods for these
biocatalysts have been comprehensively reviewed6 but there
are many ATs that display “unusual” characteristics which
require further study.
The D-phenylglycine aminotransferase (D-PhgAT), isolated
from the soil bacterium Pseudomonas stutzeri ST-20128,29
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catalyses the reversible transamination of L-glutamic acid
(L-Glu) with the amino acceptors benzoylformate (BZF) and
4-hydroxy benzoylformate (HBF) yielding the R-enantiomers
D-Phg and D-Hpg respectively. The keto product derived from
L-Glu is α-ketoglutarate (AKG) (Scheme 1). What is unique to
this AT is its so-called “stereo-inverting” characteristic, where
the amino donors (L-Glu and D-Phg) in this reversible reaction
exhibit inverse absolute configurations. Since it uses an
inexpensive L- (or S-) amino acid donor, the P. stutzeri D-PhgAT
represents an attractive biocatalyst for the synthesis of
enantiomerically pure D-Phg (or R-Phg) derivatives in a single
step.5 D-PhgAT has also been used in qualitative and
quantitative analysis of L-Glu concentrations in food when
coupled with L-glutamate dehydrogenase30 and for quality
control of amoxicillin in pharmaceuticals when coupled with a
penicillin acylase.31 The homologous D-PhgAT from P.
putida32–34 (82% amino acid sequence identity) has been
successfully combined with hydroxymandelate synthase
(HmaS) and hydroxymandelate oxidase (Hmo) to engineer an
E. coli strain that is able to produce D-Phg.34
To expand its potential as a valuable biocatalyst,
comprehensive substrate and structural analyses of the P.
stutzeri D-PhgAT are required. An understanding of the
mechanism of its unique stereo-inverting activity will also aid
in increasing its substrate scope by enzyme engineering.35 In
this study we describe the isolation of recombinant P. stutzeri
D-PhgAT and, by a combination of spectrophotometric and
chiral product analysis, we explore the amino substrate range
and enantioselectivity of this enzyme. This revealed a broader
substrate range than previously anticipated, which led us to
use this biocatalyst to prepare a range of aromatic D-amino
acids in high conversion and e.e. Furthermore, we
determined the first X-ray structure of the PLP-bound form of
the P. stutzeri D-PhgAT at 2.25 Å resolution, which confirms
its classification as a member of the class III TA family. To
explore the dual substrate binding mechanism, we then
compared the D-PhgAT structure with the PLP-bound,
external aldimine complexes of similar TAs. Furthermore, a
combined sequence and structural analysis led to site-
directed mutagenesis studies which identified potential
residues required for catalytic activity and substrate
recognition. This work lays the foundation for future enzyme
engineering, and strengthens the utility of D-PhgAT as an
important biocatalyst for the preparation of enantiopure
D-aromatic amino acids.
Results and discussion
Recombinant, codon optimized, P. stutzeri D-PhgAT was
produced in E. coli BL21 (DE3) with an N-terminal 6xHis
affinity tag. It was purified to homogeneity in high yield by
standard nickel affinity and gel-filtration chromatography
methods, which showed it to be homodimeric in solution (Fig.
S1‡). The enzyme shows a distinct UV/visible spectroscopic
profile with a λmax at 411 nm, indicative of PLP binding; this
changes upon addition of the amino donor L-Glu and leads to
PMP formation which absorbs at 311 nm (Fig. S2‡).
A convenient, high-throughput, coupled assay used the
α-ketoglutarate dehydrogenase (AKGDH) enzyme to monitor
transamination of L-Glu through NADH production (Fig. S3
and S4‡). This assay allowed the determination of kinetic
parameters (apparent KM for L-Glu and BZF are 9.85 ± 0.62
mM, 1.81 ± 0.57 mM respectively) in the “forward” D-amino
acid-producing direction (Fig. S5, Table S1‡). We confirmed
the chirality of the product using a modified Chirobiotic-T
chiral HPLC method and demonstrated the enzyme
enantioselectivity with production of D-Phg in >98% e.e. (Fig.
S6 and S7‡).36 Furthermore, we used this method to
determine the D-PhgAT kinetics, which match well with the
coupled assay (Fig. S8 and Table S1‡). With BZF as the amino
acceptor the chiral HPLC assay was used to screen D-Phg
production with various commonly used amino donors.
These included L- and D-amino acids, R- and S-α-
methylbenzylamine (MBA), isopropylamine (iPrA), as well as
o-xylene diamine (OXD) (Fig. S9 and S10‡). The production of
D-Phg is observed with several amino donors (apart from
iPrA) and the activity is ranked relative to L-Glu as the best
amino donor. This broad utility is in contrast with a previous
report which observed a very limited substrate scope.28
Regardless of the chirality of the amino donor, the
enantiopurity of the final D-Phg product is not affected. Since
L-Glu was the best amino donor it was used to scale up the
reaction with 1 g BZF substrate. Using D-PhgAT (1 mg mL−1)
93% conversion to D-Phg (99% e.e.) was observed after ∼3 h
(Fig. S11). We purified the D-Phg product by preparative
HPLC (Fig. S12‡) and characterized it using 1H and 13C NMR
and ESI-MS (Fig. S13‡) which are identical to an authentic
standard.
Since D-Phe, D-Trp and D-Tyr are used as chiral building
blocks for many clinically useful drugs, we tested the
promiscuity of the P. stutzeri D-PhgAT towards various
Scheme 1 Simplified, two-step mechanism of the D-PhgAT-catalysed
reaction. In step 1, L-Glu donates the amino group to the pyridoxal 5′-
phosphate (PLP) cofactor generating pyridoxal amine (PMP) and
α-ketoglutarate (AKG). In step 2, benzoyl formate (BZF, R = H) or its 4′-
hydroxy derivative (HBF, R = OH) accepts the amino group from PMP
yielding D-Phg or D-Hpg respectively.11
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aromatic acceptors.37–39 We used D-PhgAT with L-Glu and the
five amino acceptors (HBF, BZF, indole pyruvic acid (IPA),
phenylpyruvic acid (PPA), and 4-hydroxyphenylpyruvic acid
(HPPA)) that would yield the corresponding aromatic amino
acids D-Hpg, D-Phg, D-Trp, D-Phe, and D-Tyr (Scheme 2). The
enzyme shows good affinity towards all acceptor substrates
tested (apparent KM values from 0.79 mM for IPA to 9.24 mM
for HPPA, Table 1).
Furthermore, we found again that the conversion was
highly stereoselective with only the D-enantiomer produced
(Fig. 1). Kinetic parameters and % conversions were
calculated using the chiral HPLC method and are
summarized in Table 1. Using this data larger scale
biotransformations were carried out at up to 100 mg scale for
each amino acceptor. The D-PhgAT displayed modest to
excellent conversion for these aromatic acids, with the
highest observed for the BZF to D-Phg conversion (93%). This
analysis emphasizes the broad utility of the enzyme.
To understand the molecular basis of the substrate
promiscuity and the origin of the D-enantioselectivity, as well
as revealing the residues involved in catalysis, we determined
the crystal structure of the D-PhgAT in complex with the PLP-
cofactor bound as the internal aldimine form at 2.25 Å
resolution (Fig. 2, S14 and S15‡). Here we used the
incomplete structure of the P. stutzeri enzyme lacking the
bound PLP cofactor (PDB code: 2CY840) as a molecular
replacement model (Table S2,‡ PDB code: 6G1F). The overall
D-PhgAT structure confirmed its classification as a member
of group III of the aspartate aminotransferase family, which
falls within the type I PLP-dependent superfamily fold.41
The final refined model contains three homo-dimers of
D-PhgAT with the PLP cofactor present as an internal
aldimine bound to residue Lys269 in each chain (Fig. 2, S14
and S15‡). Each monomer can be subdivided into two
distinct domains: a small discontinuous domain comprising
the residues 1–72 and 336–453; and a large domain formed
by residues 73–335 (Fig. S14‡). The N-terminal part of the
small domain comprizes a kinked α-helix followed by a three-
stranded antiparallel β-sheet, while the C- terminal part
consists of an α-helix followed by two antiparallel β-strands,
an extended loop interspersed with a short α-helix and
continues into a longer α-helix. This is followed by a β-strand
that extends the N-terminal β-sheet and an additional
β-strand, which extends the C-terminal β-sheet, the structure
finishes with an α-helix opposed between the two other
major helices in this domain. The large domain consists of a
central seven-stranded β-sheet, with five parallel strands and
two in an anti-parallel orientation. The β-sheet is connected
by α-helices, which harbor the PLP cofactor binding site and
main dimerization interface (Fig. S14‡).
The essential Lys269 is located in the loop that connects
strands β9 and β10, with the aromatic ring of the PLP
sandwiched between Val243 and Tyr149 (Fig. S15‡). Water
molecules (red spheres) form bridges between the PLP
phosphate oxygens and the side chains of Glu124, Thr303
and the backbone of Phe304 from the opposite monomer.
The phosphate is also coordinated by H-bonds to Ser121,
Gly122 and Thr123 from the same monomer.42
Since the ATs bind two amino-acid substrates, it has been
proposed that this dual-substrate recognition is accommodated
Scheme 2 D-PhgAT reactions for the synthesis of aromatic D-amino
acids from L-Glu and aromatic amino acceptors.
Table 1 Analysis of the D-PhgAT kinetic parameters with various amino
acceptors. Kinetic parameters of D-PhgAT for five amino acceptors,
obtained using the chiral HPLC method. Reactions were carried out for
15 minutes using 100 mM L-Glu and different amino acceptor
concentrations (0–40 mM). To determine % conversions, reactions were
carried out at 100 mg scale as described in the Experimental
Substrate Conversion % ee % KM (mM) kcat/KM (M
−1 s−1)
HBF 50 >98 1.01 ± 0.07 899.15 ± 0.27
BZF 93 >98 3.16 ± 0.46 302.80 ± 0.10
IPA 30 >98 0.39 ± 0.19 262.12 ± 0.13
PPA 57 >98 6.91 ± 0.99 14.49 ± 0.82
HPPA 15 >98 9.24 ± 2.40 0.06 ± 0.01
Fig. 1 Chiral HPLC traces of the synthesis of enantiopure D-Tyr,
D-Phe, D-Trp, D-Phg and D-Hpg. Reactions described in Scheme 2 were
analysed for product formation by chiral HPLC using a Chirobiotic T
column with monitoring at λ = 205 nm.
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in two binding sites. These were named the O-pocket (or O-site,
defined by the proximity of residues to the 3′-O of the PLP) and
P-pockets (or P-site, defined by the proximity to the PLP-
phosphate) by Dijkstra and colleagues in their study of the
S-selective TA (MesAT).43 They determined the structures of this
useful enzyme with the PLP-external aldimine forms of S-β-Phe
and R-3-methylhexanoic acid, as well as with the amino
acceptor AKG. These complexes allowed them to identify
residues in the binding pockets as well as a pair of key arginine
residues (Arg54 and Arg412) in this type I enzyme. The O- and
P-pocket hypothesis was also explored by a comprehensive
structural and sequence analysis of the AT superfamily recently
carried out by Bornscheuer and colleagues to identify 13 key
residues (including specific arginines) that they propose as
crucial in controlling substrate binding and reaction
specificity.11 Bornscheuer and others have also put forward an
elegant model known as the ‘arginine flip or switch’ that is
thought to control the dual specificity of these enzymes.44–47 By
modelling into the incomplete apo D-PhgAT structure (2CY8)
they suggested that a key Arg residue, equivalent to Arg407 in
our structure, binds to the α-carboxylate of the L-Glu donor and
may switch in and out of the active site. A recent paper by
Walton et al. also determined the crystal structure of D-PhgAT
(PDB code: 6DBS) and they used this to propose a two pocket
substrate binding model and residues involved in catalysis.48
Unfortunately, like 2CY8, the D-PhgAT had no PLP bound (but
instead had phosphate) and lacked defined electron density for
important residues 28–36 and 292–302.42,48 These incomplete
apo- and phosphate-bound structures are missing important
features such as the P-pocket. In contrast, with the PLP bound
in our structure we can now better define both pockets for the
first time (Fig. 2B). The O-pocket is formed by the side chains
of Phe63, His66, His213, Phe304, and Arg407. On the other side
of the PLP cofactor the P-pocket is formed by residues Arg34,
Gln301, and Thr303.
The enzyme is unusual in that it can bind both L- and D-
forms of the amino acid substrates (e.g. L-Glu and D-Phg)
depending on which reaction (forward or reverse) it is
catalyzing (Schemes 1 and 2). This inherent substrate
promiscuity of the enzyme and the product enantioselectivity
appears to be due to a combination of these two pockets
(Fig. 2B) and a cavity (Fig. 2C) that can accommodate large
hydrophobic amino acceptors. This cavity extends from the
surface of the protein and has a wide mouth with a
constriction near the active site formed by the side chains of
His66 and His213. This constriction accommodates
hydrophobic substrates through pi-stacking interactions,
while orienting the keto substrate to accept the amine group
from the PMP intermediate. This results in the formation of
the key PLP:substrate external aldimine intermediate that
undergoes the enantiomeric H+ transfer at C4′ to form the
D-product (Fig. S16‡). We were also struck by the pair of
arginine residues provided by one of the subunits, Arg34 (in
the P-pocket) and Arg407 (in the O-pocket) (Fig. 2B). In the
PLP bound structure, in the absence of an L-amino acid
donor or a D-amino acid product, both of the side chains are
orientated away from their respective pockets but are free to
move upon ligand binding.
To understand how D-PhgAT bound its substrates Walton
et al. superimposed the active sites of their PLP-free structure
with MesAT with PLP and AKG (PDB: 2YKX), MesAT with
Fig. 2 Crystal structure of P. stutzeri D-PhgAT. (A) Functional dimer of
the D-PhgAT protein, shown with one chain as a surface representation
and the other as a cartoon showing the position of the PLP cofactor in
stick representation. (B) Active site pockets of the D-PhgAT protein
showing the PLP internal aldimine and key residues in the substrate
binding pockets. The O- and P-pockets are labelled following the
convention in Wybenga et al.43 the protein backbone is shown as a
cartoon, with key residues shown as sticks. The two chains in the
structure are coloured green and blue. The final experimental 2mFo-
DFc electron density for the PLP is shown as blue mesh. (C) Cut-away
view of the substrate binding tunnel showing the depth and breadth of
the active site region of the protein. Amino acids and PLP internal
aldimine are shown as stick representations.
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PLP:(S)-3-phenyl-β-alanine (PDB: 2YKY) and a GSAM AT with
PLP:(4S)-4,5-diaminopentanoate (PDB: 2HP2).48 The Arg54
and Arg412 side chains of MesAT were proposed to be
equivalent residues to the Arg34 and Arg407 respectively in
D-PhgAT. This allowed the “missing” Arg34 in the P-pocket to
be proposed as the residue that engages the sidechain of the
various substrates e.g. the γ-carboxylate of L-Glu. Similarly, in
the O-pocket Arg407 is thought to interact with the
carboxylate at the C-α of amino acids such as L-Glu.
Now with the Arg34-containing loop observed, we carried
out similar structural comparisons of our PLP-bound
structure with other TA enzymes to gain further insight into
the residues involved in ligand binding in both pockets. We
superimposed our PLP-bound internal aldimine structure
with TAs that have structures with useful bound ligands.
Here we used an interesting pair of S-selective ω-TAs, Bacillus
megaterium (BM-ωTA) and Arthrobacter Ars-ωTA studied by
Dijkstra and colleagues.49 These enzymes share 95%
sequence identity but surprisingly display somewhat different
substrate profiles and structural studies revealed insights
into their mechanism and specificity. The X-ray structure of
the PLP:R-MBA external aldimine bound complex of the BM-
ωTA (PDB code: 5G09,)49 showed the phenyl group of R-MBA
binding in the O-pocket and methyl group in the P-pocket.
Fig. 3 Structural comparison of D-PhgAT with other aminotransferases. (A) Overlay of the P. stutzeri DPhgAT apo (6DVS, pink sticks) and PLP
internal aldimine (6G1F, green and cyans cartoons and sticks) structures with the PLP:R-α-methylbenzylamine (R-α-MBA) external aldimine
complex of the B. megaterium S-selective aminotransferase (5G09, orange). In the B. megaterium complex Arg442 swings away from the position
of the ring of the R-α-MBA to accommodate this bulky intermediate. The equivalent residue in the P. stutzeri structure is Arg407, which is found in
different conformations in the apo- and PLP-bound structures. (B) Overlay of the D-PhgAT:PLP internal aldimine with the PLP-external aldimine of
Ars ω-TA PLP:L-Ala external aldimine complex (5G2Q). In Ars ω-TA PLP:L-Ala structure, the side chain of Arg442 swings in to interact with the C-α
carboxylate of the PLP:L-Ala, this is a 180° flip around the CG of the arginine side chain in comparison to the B. megaterium structure. (C)
Schematic representation of the dual substrate recognition mechanisms of D-PhgAT and the role of Arg34 and Arg407 in the arginine flip/switch
model. In the forward direction the ‘flipping’ Arg407 in the O-pocket is involved in the recognition of the α-carboxylic group of amino donor
L-Glu and can move out of the active site to accommodate the benzyl ring of the product D-Phg. In the P-pocket, the Arg34 side chain is involved
in recognition of the α-carboxylate of the L-Glu (and L-Asp) amino donor.
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Dijkstra and colleagues found that the O-pocket is large
enough to accommodate the phenyl group, in contrast to the
smaller P-pocket. The structure also revealed why this PLP:R-
MBA external intermediate was captured in the unproductive
state - the amine of the lysine 298 side chain is unable to act
as a base since it is on the wrong face to remove the proton
from C-α. By simply inverting the stereochemistry at C-α to
the productive S-MBA configuration the enzyme could
achieve the optimal orientation for catalysis. The D-PhgAT
also prefers S-MBA to R-MBA (Fig. S9‡) suggesting a similar
discrimination mechanism.
A comparison of the two structures (Fig. 3A) shows how
this substrate could be accommodated into the O-pocket; in
the BM-ωTA:PLP:R-MBA complex the Arg442 is swung out to
make way for the phenyl ring and Arg407, the equivalent
residue in D-PhgAT, is also swung out. Since D-PhgAT prefers
L-Ala, L-Glu and L-Asp over their opposite enantiomers we also
carried out a comparison (Fig. 3B) of the structure of the
Arthrobacter Ars-ωTA in complex with the PLP:L-Ala external
aldimine (5G2Q). In Ars-ωTA the side chain of Arg442 is
proposed as the arginine switch; swung out in the PLP-bound
complex and swung in to engage with the C-α carboxylate
when L-Ala binds. Our overlay of suggests the D-PhgAT Arg407
residue plays the equivalent flipping role to Arg442 in Ars-
ωTA. Our models also suggests that residues His66, His213
from one monomer and Thr303 from the partner monomer
play a role in the enantioselective mechanism of the enzyme.
These residues orientate the ligand to be protonated by
Lys269 from the Si-face of the PLP-bound intermediate,
generating the D-Phg enantiomer (Fig. 2B, S15 and S16‡).
We also used this structural analysis to rationalize the L-
to D-stereoinversion selectivity of D-PhgAT. Proton transfer of
the C-4′ of the resulting PLP:quinonoid intermediate is the
key to the enantioselectivity and Jomrit et al., determined
that this occurred from the Si face of the intermediate.50 The
L-Glu and D-Phg must bind in inverted orientations with
respect to each other. The aromatic side chain of D-Phg (and
the other aromatic amino acids we generated) must therefore
exchange for the C-α carboxylate of L-Glu (O-pocket) and,
similarly, the carboxylate at C-α of D-Phg can swap into the
site (P-pocket) that binds the γ-carboxylate of the L-Glu side
chain. This conformational flexibility requires mobile side
chains in the two pockets and the two arginine residues (R34
and R407) have the ability to provide such dynamic
movement. They are ideally placed to be able to swing in to
engage with carboxylate residues directly in electrostatic
interactions. Clearly, the active site must be highly dynamic
during catalytic cycles that bind and release amino acceptors
and products, depending on which direction it is operating
(Schemes 1 and 2). Moreover, we also noted the presence of
Q301 in the P-pocket in our structure, and this adds further
weight to its important role in the catalytic mechanism. The
importance of Q301 was identified in a recent cell-free
extract, high-throughput, saturation mutagenesis screen of
D-PhgAT catalysing the reverse reaction of D-Phg conversion
to L-Glu.48 This contrasts with our assay which monitors
aromatic amino acid production and AKG release. In their
screen Walton et al. focused on three residues in the
O-pocket (H66, H213 and R407) and two, in what they
predicted, in the absence of defined electron density, to be
the P-pocket (R34 and Q301). It is interesting to note that,
like us, they also found D-PhgAT displayed some substrate
promiscuity – D-Phg was the best substrate but also showed
∼8.6% relatively activity with D-Trp and ∼82% relative activity
with (S-)-4-phenyl-4-aminobutyrate.
We gained further insight into the properties of D-PhgAT by
carrying out a sequence alignment of the two D-PhgATs from P.
stutzeri and P. putida with well characterized ATs from the same
group III fold, but with opposite product enantioselectivity (Fig.
S17‡). This revealed that the key residues (Arg34, His66,
His213, Gln301 and Arg407) identified in our structural
analysis are found only in the stereo-inverting enzymes (also
referred to as R-selective) that produce D-products from
L-amino acid donors. This suggests that this stereo-inverting
property has arisen from using the group III TA fold and
incorporating these four key amino acids. Since we found these
arginine residues in the active site, we carried out a targeted
mutagenesis study and mutants of these two residues, R34A
and R407A, as well as the two histidine residues, H66A and
H213A, were obtained. We also included the Q301A mutant to
allow comparison with the recent results presented by Walton
et al.48 The results of this mutagenesis study, summarized in
Table 2, show the effect of these changes on the affinity and
catalytic efficiency towards both L-Glu and BZF in the forward,
D-Phg synthesis direction.
As we predicted, the two arginine mutants R34A and
R407A displayed a much lower affinity towards L-Glu with a
KM of 368.33 (∼14 fold) and 133.50 mM (∼5 fold) respectively
vs. the wild-type KM of 26.17 mM. The kcat and the catalytic
efficiency is substantially disrupted by the mutations for both
substrates by approximately 200- and 20-fold respectively.
The proposed role of Arg34 as a key residue in binding L-Glu
is strengthened since we found it was not possible to saturate
the enzyme with the highest achievable concentration of
L-Glu in the assay (500 mM). Like all AT enzymes, the
catalytic cycle involves many PLP-derived intermediates
including the true amine donor PMP which delivers the –NH2
group to AKG to give D-Phg in that direction. In the absence
of PLP-bound intermediate structures we used our combined
sequence, structural and mutagenesis results to envisage how
the substrates and products are recognized (Fig. 3C). We
suggest that Arg407 is the key “flipping” residue that
recognizes the C-α carboxylate of the L-Glu amino donor as
well as being able to make way for the side chains of the
aromatic products. Its partner Arg34 is involved in the
recognition of the amino donor side chain carboxylic acid
group, L-Glu is preferred but the shorter L-Asp can also be
accepted. This arginine ‘switch’ and substrate promiscuity
requires a flexible side chain and the mobility of Arg407 was
revealed by comparing our PLP-bound structure with the two
apo-D-PhgAT structures (PDBID:2CY8 and PDBID:6DVS).40,50
We found that this sidechain adopts a different orientation
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in each structure, suggesting that it is able to move to
accommodate substrate binding during catalysis (Fig. 4).
The H213A mutant was totally inactive in all the tested
conditions, suggesting that this residue is crucial to
positioning the substrate in the O-pocket. This is in contrast
to the H213A mutant described by Walton et al. which
displays ∼45% activity in the reverse direction. Interestingly,
H213N was 150% more active than the wild type but a
rationale for this dramatic increase is not clear. In our hands
both the H66A and Q301A mutants retained some activity and
by analysis of the structure we suggest that these residues are
involved in amino-acceptor binding and a hydrogen bonding
network surrounding the PLP cofactor respectively (Fig. S15‡).
Similarly, in their screen Walton et al. found that mutations
at H66 and Q301 resulted in diminished activity.
Conclusions
In conclusion, using the P. stutzeri D-PhgAT we describe a
biocatalytic approach to a preparative-scale synthesis of D-Phg
in high % e.e. and yield. The widespread use of PLP-
dependent ATs for industrial biotechnology has been
hampered by the unfavorable reaction equilibrium towards
product formation. This can be overcome by the use of
“smart amine donors”, coupled recycling systems or removal
of the keto co-product.24,51,52 Unfortunately, the commonly
used iPrA was not accepted by D-PhgAT so here we used a
large excess of the inexpensive amino donor L-Glu (∼20 times
KM) to drive the equilibrium towards product formation. Our
optimized system gives conversions (93%) that are higher
than those previously reported.28
Fig. 4 Comparison of apo- and PLP-bound forms of D-PhgAT highlights the mobility and movement of Arg407 and loops around PLP-binding site.
Our PLP-bound structure shown in salmon with two apo-forms in orange (PDBID: 2CY8) and blue (PDBID: 6DVS). The disordered, flexible loops,
defined only in the PLP-bound structure, are shown as red ribbons with terminal ordered residues labelled and shown as sticks. For clarity the inset
shows a zoom in of the positions of the Arg407 residue in each structure.
Table 2 Kinetic analysis of the D-PhgAT mutants. Summary of the kinetic parameters of D-PhgAT WT and mutants for the BZF and L-Glu substrates
D-PhgAT
L-Glu BZF
KM (mM) kcat (s
−1) kcat/KM (M
−1 s−1) KM (mM) kcat (s
−1) kcat/KM (M
−1 s−1)
WT 26.17 ± 3.63 1.65 ± 0.12 63.21 ± 0.78 3.16 ± 0.46 0.95 ± 0.056 302.80 ± 0.10
R34Aa 368.33 ± 18.78 0.111 ± 0.0088 0.304 ± 0.004 0.842 ± 0.15 0.079 ± 0.016 93.33 ± 0.037
R407A 133.50 ± 30.5 0.42 ± 0.012 3.22 ± 0.09 1.51 ± 0.45 0.169 ± 0.012 112.98 ± 0.12
H66A 9.65 ± 0.32 0.092 ± 0.006 9.76 ± 0.009 11.66 ± 5.95 0.078 ± 0.01 9.57 ± 0.09
H213A — — — — — —
Q301A 43.23 ± 7.90 0.38 ± 0.015 20.59 ± 0.020 9.02 ± 0.95 0.15 ± 0.012 16.43 ± 0.05
a The KM could not be accurately determined as the highest achievable amount of L-Glu in the reaction was 500 mM.
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A recent report described the engineering of three
recombinant E. coli strains that co-expressed four, seven and
nine enzymes, including the P. stutzeri D-PhgAT as the final step.
These whole cell biotransformations produced a range of D-Phg
derivatives in one pot from racemic mandelic acid, styrene and
L-Phe starting materials.53 Since we have shown the D-PhgAT to
be a versatile biocatalyst in being able to use a range of amino
acceptors it suggests that similar cascades could be constructed
to allow conversion of simple building blocks to produce a
variety of enantiopure aromatic D-amino acids.53
The determination of the first crystal structure of the
D-PhgAT with its bound PLP cofactor has shed light on the
unique stereo-inverting and enantioselective properties of the
enzyme. The broad substrate scope is explained by a large active
site cavity and two pockets each containing an essential Arg
residue that is crucial for the catalytic activity. Our study
highlights key active site residues that are involved in the
catalytic mechanism and potentially control the exquisite
R-selectivity of the enzyme. These features suggest that the
O-pocket of D-PhgAT could be engineered to accept even bulkier
pro-chiral substrates and convert them to enantiopure R-
products. Our study paves the way for D-PhgAT engineering in
order to further expand the substrate scope of this enzyme.54,55
In future, structures of the enzyme with substrates and products,
combined with a directed evolution campaign, will allow the
product scope of D-PhgAT to be further expanded to take
advantage of the unique properties of this versatile biocatalyst.
Experimental
General
Standard chemical reagents (D-Phg, D-Hpg, or other amino
acids, CoASH, buffers) and enzymes were from Sigma, VWR,
Alfa Aesar and Acros Organic.
Cloning and protein expression
The full-length, codon optimized dpgA gene (Pseudomonas
stutzeri ST-201, UNIPROT code: Q6VY99) was purchased from
GenScript and cloned into pET 15b plasmid to give a
recombinant D-PhgAT with a non-cleavable N-terminal His6-
tag. The construct was used to transform E. coli BL21 (DE3)
competent cells and selection was carried out on agar plates
containing ampicillin (100 μg mL−1; LB/Amp100). A single
colony was used to inoculate 250 mL of LB/Amp100 broth and
the overnight culture was grown at 37 °C with shaking at 250
rpm. The overnight culture was used to inoculate 1 L of fresh
LB/Amp100 broth and grown to an A600 of 0.6–0.9. Protein
expression was induced by addition of IPTG to a final
concentration of 0.1 mM and growth was continued for 16 h
at 20 °C. Cells were harvested by centrifugation (Thermo
Scientific Multicentrifuge X3R) at 4000 × g for 30 min at 4 °C.
Site directed mutagenesis
The D-PhgAT R34A, H66A, H213A, Q301A and R407A
mutants were constructed according to the overlapping
primer site-directed mutagenesis (SDM) method with the
primer pairs outlined in the supporting information.
Colonies were picked and sequenced, and based on the
results, mutants were taken forward for analysis. The mass
of each D-PhgAT mutant was confirmed by LC electrospray
ionization mass spectrometry (ESI-MS).
D-PhgAT purification
All purification steps were carried out at 4 °C. Cells were
resuspended in lysis buffer (0.1 M CAPS pH 9.5, 150 mM
NaCl, 20 mM imidazole, 50 μM PLP) with the addition of
DNase (0.2 mg per 10 mL buffer) and lysed by sonication for
15 cycles (30 s on, 30 s off). The lysed cell suspension was
cleared by centrifugation (Thermo Scientific Multicentrifuge
X3R) at 14 000 × g for 40 min at 4 °C. The cell-free extract was
loaded onto a 1 mL HisTrap nickel affinity column (GE
Healthcare). The column was washed with binding buffer for
20 column volumes, then the protein eluted with an
imidazole gradient (10 to 500 mM) over 30 column volumes.
Protein containing fractions were analysed by 12% SDS-PAGE
and concentrated to 1 mL using the Vivaspin 20 MWCO
30000 (Sartorius). The concentrated D-PhgAT was loaded onto
a pre-equilibrated (0.1 M CAPS, 150 mM NaCl, 50 μM PLP)
HiPrep™ 16/600 Superdex™ S-200 size exclusion column
(120 mL). Recombinant protein was eluted at a flow rate of 1
mL min−1 in buffer. The purity of the recombinant proteins
was analysed by 12% SDS-PAGE.
Spectroscopic analysis
All UV-visible spectra were recorded on a single-beam Cary 50
UV-vis spectrometer and analysed using Origin. To convert
the apo-D-PhgAT to the holo-D-PhgAT form the enzyme was
dialyzed for 2 h at 4 °C against 0.1 M CAPS (pH 9.5)
containing 150 μM NaCl and 50 μM PLP. Excess PLP was
removed by passing the protein through a PD-10 (Sephadex
G- 25M) de-salting column (GE Healthcare) before any
spectrophotometric measurements were taken. The
concentration of recombinant D-PhgAT was 20 μM and the
spectrophotometer was blanked with 0.1 M CAPS (pH 9.5)
containing 150 mM NaCl and 50 μM PLP.
α-Ketoglutarate dehydrogenase assay (AKGDH assay)
The D-PhgAT activity was monitored by coupling the
reaction with the α-ketoglutarate dehydrogenase (AKGDH)
since α-ketoglutarate (AKG) is the product of the first half
reaction. The final volume of the reactions was 250 μl and
contained 0.1 M CAPS pH 9.5, 150 mM NaCl, 1 mM MgCl2,
1 mM CaCl2, 0.05 mM EDTA, 50 μM PLP, 1 mM CoASH, 3
mM NAD+, 0.2 U KGDH, 0 to 50 mM L-Glu, 0 to 20 mM
benzylformate (BZF). These reagents were pre-incubated at
35 °C and the reaction was blanked. The reaction was
initiated by adding 1 μM D-PhgAT. The increase in
absorbance at 340 nm resulting from the enzymatic
conversion of NAD+ to NADH after AKG production by the
D-PhgAT was monitored over 1 h on a BioTek Synergy HT
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plate reader with Costar 96-well plate. The data from the
first 15 min were analyzed using the Michaelis–Menten
model and a nonlinear regression fit on GraphPad gave
values of KM and kcat (εNADH = 6220 M
−1 cm−1).
High performance liquid chromatography (HPLC) analysis
For the HPLC method, reactions containing 0.51 mg mL−1
D-PhgAT, 0–200 mM L-Glu, 0–20 mM amino acceptors (BZF/
HBZF/IPA/PPA/HPA) in 0.1 M CAPS pH 9.5, 150 mM NaCl, 50
μM PLP buffer were incubated at 37 °C before being
terminated at 15 minutes by diluting 40 fold in the chiral
mobile phase: 0.025% triethylammonium acetate (TEAA) :
MeOH (50 : 50). Reactions were then analysed by chiral HPLC
using a Chirobiotic T column (Astec, chiral phase
Teicoplanin, 5 μm, 250 mm × 4.6 mm) and the following
isocratic conditions: mobile phase: 0.025% TEAA :MeOH
(50 : 50, v/v), flow rate: 1 mL min−1, λ: 205 nm, temperature:
RT, run time: 30 min. The column was calibrated with single
enantiomers of the amino acids. The conversion was used to
measure enzyme activity. For the detection of non-natural
substrates such as D-phenylalanine, D-tyrosine and
D-tryptophan the same procedure was applied. Lab solution
software (Shimadzu) was used to measure the area under the
product peaks. To determine the kinetic parameters,
reactions were carried out in triplicate and quenched after 15
minutes by 1 : 40 dilution in the chiral mobile phase. The
data were analyzed using the Michaelis–Menten model and a
nonlinear regression fit on GraphPad The data points were
taken as the average values, with the errors calculated as the
standard deviations.
Amino donor screening
A D-PhgAT aliquot was thawed and incubated on ice with 50
μM PLP for ∼2 h in order to be sure it was fully loaded with
fresh PLP.
Reactions containing 0.51 mg mL−1 D-PhgAT, 10 mM L/D
amino donor, 10 mM BZF in 0.1 M CAPS pH 9.5, 150 mM
NaCl, 50 μM PLP buffer were incubated at 37 °C before being
terminated at 18 h by diluting 40-fold in the chiral mobile
phase. Reactions were then analysed by chiral HPLC using a
Chirobiotic-T column as stated before. Percentage
conversions were normalized relative to L-Glu as the best
amino donor.
Biotransformation reactions
The large scale biotransformation was performed in a 100
mL conical flask in a final volume of 20 mL. For each
component of the reaction the pH was adjusted to 9.5 before
being added to the reaction mixture. Freshly purified
D-PhgAT (loaded with PLP) was added at a final concentration
of 0.2 mg mL−1, 0.4 mg mL−1 or 1 mg mL−1 (4 μM, 8 μM, 20
μM) in 0.1 M CAPS buffer pH 9.5, 150 mM NaCl, 50 μM PLP
containing 1 g of BZF (∼133 mM) and 500 mM L-Glu. The
biotransformation was carried out at 37 °C at 120 rpm. A
negative control with all the reagents omitting the enzyme
was performed at the same time. Time points were collected
at time 0, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8
h, 9 h, 24 h, 36 h. Each time point was collected in triplicated
and processed as described above. At each time point
reactions were terminated by diluting 40 fold in the chiral
mobile phase and analysed by HPLC.
X-ray crystallography
Purified D-PhgAT, at 9.1 mg mL−1, was crystallized by
hanging-drop vapor diffusion at 18 °C. Yellow crystals were
produced by adding 1 μL of 9.1 mg mL−1 D-PhgAT in 0.1 M
CAPS (pH 9.5), 150 mM NaCl, 50 μM PLP to 1 μL of 0.1 M
TrisHCl (pH 7.5), 0.2 M MgCl2, 10% (v/v) polyethylene glycol
8000 (PEG 8000). Crystals were cryo-protected with a solution
containing 0.1 M TrisHCl (pH 7.5), 0.2 M MgCl2, 10% (v/v)
polypropylene glycol 8000, 20% (v/v) polypropylene glycol 200
PEG and then flash-cooled by immersion in liquid nitrogen.
Datasets were collected on beamline I03 at the Diamond
Light Source (Didcot, UK) at 100 K using a Pilatus 6 M
detector. Diffraction data were integrated and scaled using
XDS 46 and symmetry-related reflections were merged with
Aimless. The resolution cut off used for structure
determination and refinement was determined based on the
CC1/2 criterion proposed by Karplus and Diederichs. The
structure of D-PhgAT was determined by molecular
replacement using the D-PhgAT incomplete structure with the
PDB code 2CY8. A single solution comprising three dimers in
the asymmetric unit was found using Phaser. The initial
model was rebuilt using Phe-nix.autobuild followed by cycles
of refinement with Phenix.refine and manual rebuilding in
Coot. The final model was refined with automatically
determined TLS groups and isotropic B-factors. The model
was validated using MolProbity. Structural superimpositions
were calculated using Coot. Crystallographic figures were
generated with PyMOL (Schrodinger LLC). Data collection
and refinement statistics are shown in Table S2.‡ X-ray
diffraction images are available online at Zendo (doi:10.5281/
zenodo.1059413).
Crystal structures were overlayed using the Pymol Align
feature within Pymol (The PyMOL Molecular Graphics
System, Version 1.2r3pre, Schrödinger, LLC). The RMSD
values for each overlay are: 6G1F with 5G2Q – 2.18 Å over
1610 atoms; 6G1F with 5G09 – 2.12 Å over 1546 atoms; 6G1F
with 6DVS – 0.351 Å over 2205 Å.
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